Immunocompetence and prognosis in patients with gynecologic cancer.
D000230:Adenocarcinoma / Q000276:immunology*; D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D000946:Antigens, Fungal; D000956:Antigens, Viral; D002175:Candida / Q000276:immunology; D002277:Carcinoma / Q000276:immunology*; D002278:Carcinoma in Situ / Q000276:immunology; D003045:Coccidioides / Q000276:immunology; D004139:Dinitrofluorobenzene / Q000276:immunology; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology*; D006659:Histoplasmin / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D007271:Injections, Intradermal; D009109:Mumps virus / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology; D011379:Prognosis; D011506:Proteins / Q000276:immunology; D012882:Skin Tests; D013299:Streptodornase and Streptokinase / Q000276:immunology; D014249:Trichophyton / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology; D014594:Uterine Neoplasms / Q000276:immunology
D000946:Antigens, Fungal; D000956:Antigens, Viral; D011506:Proteins; D006659:Histoplasmin; D004139:Dinitrofluorobenzene; D013299:Streptodornase and Streptokinase